TERCONAZOLE- terconazole suppository
G & W Laboratories, Inc.
Vaginal Suppositories 80 mg
Terconazole Vaginal Suppositories are white to off-white suppositories for intravaginal administration
containing 80 mg of the antifungal agent terconazole, cis-1-[p-[[2-(2,4-Dichlorophenyl)-2-(1H-1,2,4-
triazol-1-ylmethyl)-1, 3-dioxolan-4-yl]methoxy]phenyl]-4-isopropylpiperazine, in triglycerides derived
from coconut and/or palm kernel oil (a base of hydrogenated vegetable oils) and butylated
The structural formula of terconazole is as follows:
Terconazole, a triazole derivative, is a white to almost white powder with a molecular weight of
532.47. It is insoluble in water; sparingly soluble in ethanol; and soluble in butanol.
Following a single intravaginal application of a suppository containing 240 mg
healthy women, approximately 70% (range: 64 to 76%) of terconazole remains in the vaginal area
during the suppository retention period (16 hours); approximately 10% (range: 5 to 16%) of the
administered radioactivity was absorbed systemically over 7 days. Maximum plasma concentrations of
terconazole occur 5 to 10 hours after intravaginal application of the cream or suppository. Systemic
exposure to terconazole is approximately proportional to the applied dose, whether as the cream or
suppository. The rate and extent of absorption of terconazole are similar in patients with vulvovaginal
candidiasis (pregnant or non-pregnant) and healthy subjects.
Terconazole is highly protein bound (94.9%) in human plasma and the degree of binding is independent
of drug concentration over the range of 0.01 to 5.0 mcg/mL.
Systemically absorbed terconazole is extensively metabolized (>95%).
Across various studies in healthy women, after single or multiple intravaginal administration of
terconazole as the cream or suppository/ovule, the mean elimination half-life of unchanged terconazole
ranged from 6.4 to 8.5 hours. Following a single intravaginal administration of a suppository containing
C-terconazole to hysterectomized or tubal ligated women, approximately 3 to 10% (mean ±
SD: 5.7 ± 3.0%) of the administered radioactivity was eliminated in the urine and 2.0 to 6% (mean ± SD:
4.2 ± 1.6%) was eliminated in the feces during the 7-day collection period.
There is no significant increase in maximum plasma concentration or overall exposure (AUC) after
multiple daily applications of the cream for 7 days or suppositories for 3 days.
Photosensitivity reactions were observed in some normal volunteers following repeated dermal
application of terconazole 2% and 0.8% creams under conditions of filtered artificial ultraviolet light.
Photosensitivity reactions have not been observed in U.S. and foreign clinical trials in patients who
were treated with terconazole suppositories or vaginal cream (0.4% and 0.8%).
Mechanism of action
Terconazole, an azole antifungal agent, inhibits fungal cytochrome P-450-mediated 14 alpha-lanosterol
demethylase enzyme. This enzyme functions to convert lanosterol to ergosterol. The accumulation of
14 alpha-methyl sterols correlates with the subsequent loss of ergosterol in the fungal cell wall and
may be responsible for the antifungal activity of terconazole. Mammalian cell demethylation is less
sensitive to terconazole inhibition.
Activity in vitro
Terconazole exhibits antifungal activity in vitro against Candida albicans and other Candida species.
The MIC values of terconazole against most Lactobacillus spp. typically found in the human vagina were
≥128 mcg/mL; therefore these beneficial bacteria are not affected by drug treatment.
INDICATIONS AND USAGE
Terconazole Vaginal Suppositories, 80 mg is indicated for the local treatment of vulvovaginal
candidiasis (moniliasis). As this product is effective only for vulvovaginitis caused by the genus
Candida, the diagnosis should be confirmed by KOH smears and/or cultures.
Patients known to be hypersensitive to terconazole or to any of the components of the suppositories.
Anaphylaxis and toxic epidermal necrolysis have been reported during terconazole therapy.
Terconazole therapy should be discontinued if anaphylaxis or toxic epidermal necrolysis develops.
For vulvovaginal use only. Terconazole is not for ophthalmic or oral use. Discontinue use and do not
retreat with terconazole if sensitization, irritation, fever, chills or flu-like symptoms are reported during
The base contained in the suppository formulation may interact with certain rubber or latex products,
such as those used in vaginal contraceptive diaphragms or latex condoms; therefore concurrent use is
If there is lack of response to terconazole, appropriate microbiologic studies (standard KOH smear
and/or cultures) should be repeated to confirm the diagnosis and rule out other pathogens.
The therapeutic effect of this product is not affected by oral contraceptive usage.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Studies to determine the carcinogenic potential of terconazole have not been performed.
Terconazole was not mutagenic when tested in vitro for induction of microbial point mutations (Ames
test), or for inducing cellular transformation, or in vivo for chromosome breaks (micronucleus test) or
dominant lethal mutations in mouse germ cells.
Impairment of Fertility
No impairment of fertility occurred when female rats were administered terconazole orally up to 40
mg/kg/day for a three month period.
Pregnancy Category C
There was no evidence of teratogenicity when terconazole was administered orally up to 40 mg/kg/day
(25× the recommended intravaginal human dose of the suppository formulation) in rats, or 20 mg/kg/day
in rabbits, or subcutaneously up to 20 mg/kg/day in rats.
Dosages at or below 10 mg/kg/day produced no embryotoxicity; however, there was a delay in fetal
ossification at 10 mg/kg/day in rats. There was some evidence of embryotoxicity in rabbits and rats at 20
to 40 mg/kg. In rats, this was reflected as a decrease in litter size and number of viable young and
reduced fetal weight. There was also delay in ossification and an increased incidence of skeletal
The no-effect dose of 10 mg/kg/day resulted in a mean peak plasma level of terconazole in pregnant rats
of 0.176 mcg/mL which exceeds by 17 times the mean peak plasma level (0.010 mcg/mL) seen in normal
subjects after intravaginal administration of terconazole 80 mg vaginal suppository. This safety
assessment does not account for possible exposure of the fetus through direct transfer to terconazole
from the irritated vagina by diffusion across amniotic membranes.
Since terconazole is absorbed from the human vagina, it should not be used in the first trimester of
pregnancy unless the physician considers it essential to the welfare of the patient.
Terconazole may be used during the second and third trimester if the potential benefit outweighs the
possible risks to the fetus.
It is not known whether this drug is excreted in human milk. Animal studies have shown that rat offspring
exposed via the milk of treated (40 mg/kg/orally) dams showed decreased survival during the first few
post-partum days, but overall pup weight and weight gain were comparable to or greater than controls
throughout lactation. Because many drugs are excreted in human milk, and because of the potential for
adverse reaction in nursing infants from terconazole, a decision should be made whether to discontinue
nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Safety and efficacy in children have not been established.
Clinical studies of terconazole vaginal suppositories did not include sufficient numbers of subjects
aged 65 and over to determine whether they respond differently from younger subjects. Other reported
clinical experience has not identified differences in responses between the elderly and younger
Adverse Reactions from Clinical Trials
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed
in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug
and may not reflect the rates observed in clinical practice.
During controlled clinical studies conducted in the United States, 284 patients with vulvovaginal
candidiasis were treated with terconazole 80 mg vaginal suppositories. Based on comparative analyses
with placebo (295 patients), the adverse experiences considered adverse reactions most likely related to
terconazole 80 mg vaginal suppositories were headache (30.3% vs. 20.7% with placebo) and pain of
the female genitalia (4.2% vs. 0.7% with placebo). Adverse reactions that have also been reported but
were not statistically significantly different from placebo were burning (15.2% vs. 11.2% with placebo)
and body pain (3.9% vs. 1.7% with placebo). Fever (2.8% vs. 1.4% with placebo) and chills (1.8% vs.
0.7% with placebo) have also been reported. The adverse drug experience on terconazole most
frequently causing discontinuation was burning (2.5% vs. 1.4% with placebo) and pruritus (1.8% vs.
1.4% with placebo).
The following adverse drug reactions have been first identified during post-marketing experience with
terconazole:. Because these reactions are reported voluntarily from a population of uncertain size, it is
not always possible to reliably estimate their frequency or establish a causal relationship to drug
General: Asthenia, Influenza-Like Illness consisting of multiple listed reactions including fever and
chills, nausea, vomiting, myalgia, arthralgia, malaise
Immune: Hypersensitivity, Anaphylaxis, Face Edema
Skin: Rash, Toxic Epidermal Necrolysis, Urticaria
To report SUSPECTED ADVERSE REACTIONS, contact G&W Laboratories, Inc. at 1-800-
922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
In the rat, the oral LD values were found to be 1741 and 849 mg/kg for the male and female,
respectively. The oral LD values for the male and female dog were
1280 and ≥640 mg/kg,
In the event of oral ingestion of suppository or cream, supportive and symptomatic measures should be
carried out. If the cream is accidentally applied to the eyes, wash with clean water or saline and seek
medical attention if symptoms persist.
DOSAGE AND ADMINISTRATION
One Terconazole Vaginal Suppository (80 mg terconazole) should be administered intravaginally once
daily at bedtime for three consecutive days.
Before prescribing another course of therapy, the diagnosis should be reconfirmed by smears and/or
cultures and other pathogens commonly associated with vulvovaginitis ruled out. The therapeutic effect
of terconazole vaginal suppositories is not affected by menstruation.
Terconazole Vaginal Suppositories 80 mg are available as 2.5 g, elliptically-shaped white to off-white
suppositories in packages of three with a vaginal applicator. NDC 0713-0552-73
Store at 20°- 25°C (68°- 77°F) [see USP Controlled Room Temperature].
G&W Laboratories, Inc.
South Plainfield, NJ 07080
Suppositories 80 mg
Three oval suppositories, for use inside the vagina only.
Designed to be inserted into the vagina.
HOW TO USE:
Place one suppository into the vagina each night at bedtime, for 3 nights, as directed by your doctor.
The terconazole vaginal suppository is self-lubricating and may be inserted with or without the
A. Insertion with the applicator
1. Filling the applicator
Break off suppository from the plastic strip.
Pull the plastic completely apart at the notched end.
Place the flat end of the suppository into the
open end of the applicator as shown. You are
now ready to insert the suppository into the
2. Using the applicator
Lie on your back with your knees drawn up toward your chest.
Holding the applicator by the ribbed end of the barrel, gently insert it into the vagina as far as it will
Press the plunger to release the suppository into the vagina.
Remove the applicator from the vagina.
3. Cleaning the applicator
After each use, you should thoroughly clean the applicator by following the procedure below:
Pull the plunger out of the barrel.
Wash both pieces with lukewarm, soapy water, and dry them thoroughly.
Put the applicator back together by gently pushing the plunger into the barrel as far as it will go.
B. Insertion without the applicator
Lie on your back with your knees drawn up toward your chest.
Place the suppository on the tip of your finger as shown.
Insert the suppository gently into the vagina as far as it will comfortably go.
NOTE: Store the suppositories at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. See
end flap of carton or suppository label for lot number and expiration date.
A WORD ABOUT YEAST INFECTIONS
Why do yeast infections occur?
Yeast infections are caused by an organism called Candida (KAN di duh). It may be present in small and
harmless amounts in the mouth, digestive tract, and vagina. Sometimes the natural balance of the vagina
becomes upset. This may lead to rapid growth of Candida, which results in a yeast infection. Symptoms
of a yeast infection include itching, burning, redness, and an abnormal discharge.
Your doctor can make the diagnosis of a yeast infection by evaluating your symptoms and looking at a
sample of the discharge under the microscope.
How can I prevent yeast infections?
Certain factors may increase your chance of developing a yeast infection. These factors don't actually
cause the problem, but they may create a situation that allows the yeast to grow rapidly.
Clothing: Tight jeans, nylon underwear, pantyhose, and wet bathing suits can hold in heat and
moisture (two conditions in which yeast organisms thrive). Looser pants or skirts, 100% cotton
underwear, and stockings may help avoid this problem.
Diet: Cutting down on sweets, milk products, and artificial sweeteners may reduce the risk of yeast
Antibiotics: Antibiotics work by eliminating disease-causing organisms. While they are helpful in
curing other problems, antibiotics may lead to an overgrowth of Candida in the vagina.
Pregnancy: Hormonal changes in the body during pregnancy encourage the growth of yeast. This is
a very common time for an infection to occur. Until the baby is born, it may be hard to completely
eliminate yeast infections. If you believe you are pregnant, tell your doctor.
Menstruation: Sometimes monthly changes in hormone levels may lead to yeast infections.
Diabetes: In addition to heat and moisture, yeast thrives on sugar. Because diabetics often have
sugar in their urine, their vaginas are rich in this substance. Careful control of diabetes may help
prevent yeast infection.
Controlling these factors can help eliminate yeast infections and may prevent them from coming back.
Some other helpful tips:
1. For best results, be sure to use the medication as prescribed by your doctor, even if you feel better
2. Avoid sexual intercourse, if your doctor advises you to do so. The suppository formulation (not the
cream) may damage the diaphragm or latex condom. Therefore, use of the diaphragm or latex condom
during therapy with the suppository is not recommended. Consult your physician.
3. If your partner has any penile itching, redness, or discomfort, he should consult his physician and
mention that you are being treated for a yeast infection.
4. You can use the medication even if you are having your menstrual period. However, you should not
use tampons because they may absorb the medication. Instead, use external pads or napkins until you
have finished your medication. You may also wish to wear a sanitary napkin if the vaginal medication
5. Dry the genital area thoroughly after showering, bathing, or swimming. Change out of a wet bathing
suit or damp exercise clothes as soon as possible. A dry environment is less likely to encourage the
growth of yeast.
6. Wipe from front to rear (away from the vagina) after a bowel movement.
7. Don't douche unless your doctor specifically tells you to do so. Douching may disturb the vaginal
8. Don't scratch if you can help it. Scratching can cause more irritation and spread the infection.
9. Discuss with your physician any medication you are already taking. Certain types of medication can
make your vagina more susceptible to infection.
10. Eat nutritious meals to promote your general health.
G&W Laboratories, Inc.
South Plainfield, NJ 07080
PRINCIPAL DISPLAY PANEL - 80 mg Suppository Blister Pack Carton
WITH VAGINAL APPLICATOR
Keep this and all medications out of the reach of children.
Product T ype
HUMAN PRESCRIPTION DRUG
Ite m Code (Source )
NDC:0 713-0 552
Route of Administration
G & W Laboratories, Inc.
Active Ingredient/Active Moiety
Basis of Strength
Stre ng th
Terco na zo le (UNII: 0 KJ2VE6 6 4U) (Terco nazo le - UNII:0 KJ2VE6 6 4U)
Te rc o na z o le
8 0 mg
Stre ng th
co co nut o il (UNII: Q9 L0 O73W7L)
pa lm kernel o il (UNII: B0 S9 0 M0 233)
butyla ted hydro xya niso le (UNII: REK49 6 0 K2U)
WHITE (white to o ff-white)
S hap e
S iz e
Marketing Start Date
Marketing End Date
NDC:0 713-0 552-73
3 in 1 CARTON
1 in 1 BLISTER PACK; Type 0 : No t a Co mbinatio n Pro duct
Marke ting Cate gory
Application Numbe r or Monograph Citation
Marke ting Start Date
Marke ting End Date
0 9 /25/20 15
G & W Laboratories, Inc. (001271188)
T aro Pharmaceuticals U.S.A., Inc. (145186370)
Ad d re s s
Busine ss Ope rations
G & W Labo rato ries, Inc.
0 0 127118 8
MANUFACTURE(0 713-0 552)